ArticleFrontiers in pharmacology2025

Disproportionality analysis of safety signals for milnacipran and levomilnacipran: a pharmacovigilance study using the FDA adverse event reporting system.

Tao Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.